Intelligent nanomaterials for medicine: Carrier platforms and targeting strategies in the context of clinical application

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 6, 2013, Pages 742-757

  Lehner, Roman ^a   Wang, Xueya ^a   Marsch, Stephan ^a,b   Hunziker, Patrick ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b The European Foundation for Clinical Nanomedicine   (Switzerland)

Author keywords

Active targeting; Nanoplatforms; Passive targeting; Stimuli responsive nanocarriers; Targeted delivery

Indexed keywords

ACTIVE TARGETING; NANO-CARRIERS; NANOPLATFORMS; PASSIVE TARGETING; TARGETED DELIVERY;

DIAGNOSIS; DRUG DELIVERY; NANOSTRUCTURED MATERIALS; TISSUE;

INTELLIGENT AGENTS;

CARBON NANOTUBE; CHITOSAN; DENDRIMER; LIPOSOME; MACROGOL; METAL NANOPARTICLE; NANOCARRIER; NANOMATERIAL; PEPTIDE DERIVATIVE; POLYAMIDOAMINE; POLYMER; QUANTUM DOT; DRUG CARRIER; NANOPARTICLE;

ALLERGIC REACTION; CLINICAL MEDICINE; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TARGETING; GEL; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; POLYMER PRODUCTION; REVIEW; CHEMISTRY; DIAGNOSTIC USE; PROCEDURES;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOMEDICINE; NANOPARTICLES; NANOSTRUCTURES;

EID: 84880743831     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.01.012     Document Type: Review

References (208)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
2. White R.R., Sullenger B.A., Rusconi C.P. Developing aptamers into therapeutics. J Clin Invest 2000, 106:929-934.
3. Itaka K., Chung U.-I., Kataoka K. Supramolecular nanocarrier for gene and siRNA delivery. Nippon Rinsho 2006, 64:253-257.
4. Xu S., Luo Y., Graeser R., Warnecke A., Kratz F., Hauff P., et al. Development of pH-responsive core-shell nanocarriers for delivery of therapeutic and diagnostic agents. Bioorg Med Chem Lett 2009, 19:1030-1034.
5. Parveen S., Sahoo S.K. Polymeric nanoparticles for cancer therapy. J Drug Target 2008, 16:108-123.
6. Park T.G., Jeong J.H., Kim S.W. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006, 58:467-486.
7. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
8. Torchilin V.P. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006, 58:1532-1555.
9. Caracciolo G., Amenitsch H. Cationic liposome/DNA complexes: from structure to interactions with cellular membranes. Eur Biophys J 2012, 41:815-829.
10. Cukierman E., Khan D.R. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 2010, 80:762-770.
11. Sawant R.R., Torchilin V.P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol 2010, 27:232-246.
12. Tang M.-F., Lei L., Guo S.-R., Huang W.-L. Recent progress in nanotechnology for cancer therapy. Chin J Cancer 2010, 29:775-780.
13. Cho K., Wang X., Nie S. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
14. Barenholz Y.Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
15. Hofheinz R.-D., Gnad-Vogt S.U., Beyer U., Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691-707.
16. Rochlitz C., Ruhstaller T., Lerch S., Spirig C., Huober J., Suter T., et al. Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2011, 22:80-85.
17. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006, 1:297-315.
18. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32:3459-3470.
19. Geisert E.E., Del Mar N.A., Owens J.L., Holmberg E.G. Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci Lett 1995, 184:40-43.
20. Elegbede A.I., Banerjee J., Hanson A.J., Tobwala S., Ganguli B., Wang R., et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc 2008, 130:10633-10642.
21. Christie J.G., Kompella U.B. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today 2008, 13:124-134.
22. Suzuki R., Oda Y., Utoguchi N., Maruyama K. Development of ultrasonic cancer therapy using ultrasound sensitive liposome. Yakugaku Zasshi 2010, 130:1665-1670.
23. Yanagie H., Fujii Y., Takahashi T., Tomita T., Fukano Y., Hasumi K., et al. Boron neutron capture therapy using 10B entrapped anti-CEA immunoliposome. Hum Cell 1989, 2:290-296.
24. Lehner R., Wang X., Wolf M., Hunziker P. Designing switchable nanosystems for medical application. J Control Release 2012, 161:307-316.
25. Hu X., Liu S., Huang Y., Chen X., Jing X. Biodegradable block copolymer-doxorubicin conjugates via different linkages: preparation, characterization, and in vitro evaluation. Biomacromolecules 2010, 11:2094-2102.
26. Hans M., Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
27. Wang L., Zeng R., Li C., Qiao R. Self-assembled polypeptide-block-poly(vinylpyrrolidone) as prospective drug-delivery systems. Colloids Surf B Biointerfaces 2009, 74:284-292.
28. Lu J., Liong M., Zink J.I., Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 2007, 3:1341-1346.
29. Li G., Liu J., Pang Y., Wang R., Mao L., Yan D., et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. Biomacromolecules 2011, 12:2016-2026.
30. Blanco E., Kessinger C.W., Sumer B.D., Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med 2009, 234:123-131.
31. Mao C.-Q., Du J.-Z., Sun T.-M., Yao Y.-D., Zhang P.-Z., Song E.-W., et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials 2011, 32:3124-3133.
32. Jeong J.H., Mok H., Oh Y.-K., Park T.G. siRNA conjugate delivery systems. Bioconjug Chem 2009, 20:5-14.
33. Park M.R., Han K.O., Han I.K., Cho M.-H., Nah J.W., Choi Y.J., et al. Degradable polyethylenimine-poly(ethylene glycol) copolymers as novel gene carriers. J Control Release 2005, 105:367-380.
34. He C.-X., Tabata Y., Gao J.-Q. Non-viral gene delivery carrier and its three-dimensional transfection system. Int J Pharm 2010, 386:232-242.
35. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F.W., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27:2569-2589.
36. Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., et al. A new class of polymers: Starburst-dendritic macromolecules. Polym J 1985, 17:117-132.
37. Paleos C.M., Tsiourvas D., Sideratou Z., Tziveleka L.-A. Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv 2010, 7:1387-1398.
38. Tomalia D.A. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009, 11:1251-1310.
39. Mahesh L Patil MZATM. Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing. ACS Nano 2011;5:1877-1887.
40. Pavan G.M., Posocco P., Tagliabue A., Maly M., Malek A., Danani A., et al. PAMAM dendrimers for siRNA delivery: computational and experimental insights. Chemistry 2010, 16:7781-7795.
41. Navarro G. Tros de Ilarduya C. Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo. Nanomedicine 2009, 5:287-297.
42. Jia L., Xu J.-P., Wang H., Ji J. Polyamidoamine dendrimers surface-engineered with biomimetic phosphorylcholine as potential drug delivery carriers. Colloids Surf B Biointerfaces 2011, 84:49-54.
43. Zhou W., Shao J., Jin Q., Wei Q., Tang J., Ji J. Zwitterionic phosphorylcholine as a better ligand for gold nanorods cell uptake and selective photothermal ablation of cancer cells. Chem Commun 2010, 46:1479.
44. McCarthy T.D., Karellas P., Henderson S.A., Giannis M., O'Keefe D.F., Heery G., et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005, 2:312-318.
45. O'Loughlin J., Millwood I.Y., McDonald H.M., Price C.F., Kaldor J.M., Paull J.R.A. Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel (R)): a dose ranging, phase I study. Sex Transm Dis 2010, 37:100-104.
46. Price C.F., Tyssen D., Sonza S., Davie A., Evans S., Lewis G.R., et al. SPL7013 gel (VivaGel (R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. Plos One 2011, 6:e24095.
47. Donaldson K. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006, 92:5-22.
48. Kim K.Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 2007, 3:103-110.
49. Beg S., Rizwan M., Sheikh A.M., Hasnain M.S., Anwer K., Kohli K. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol 2010, 63:141-163.
50. Gu Y.-J., Cheng J., Jin J., Cheng S.H., Wong W.-T. Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells. Int J Nanomedicine 2011, 6:2889-2898.
51. Lanone S., Boczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med 2006, 6:651-663.
52. Poland C.A., Duffin R., Kinloch I., Maynard A., Wallace W.A.H., Seaton A., et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008, 3:423-428.
53. Zhu L., Chang D.W., Dai L., Hong Y. DNA damage induced by multiwalled carbon nanotubes in mouse embryonic stem cells. Nano Lett 2007, 7:3592-3597.
54. Ji S.-R., Liu C., Zhang B., Yang F., Xu J., Long J., et al. Carbon nanotubes in cancer diagnosis and therapy. BBA - Rev Cancer 1806, 2010:29-35.
55. Villa C.H., McDevitt M.R., Escorcia F.E., Rey D.A., Bergkvist M., Batt C.A., et al. Synthesis and biodistribution of oligonucleotide-functionalized, tumor-targetable carbon nanotubes. Nano Lett 2008, 8:4221-4228.
56. Ji Z., Lin G., Lu Q., Meng L., Shen X., Dong L., et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J Colloid Interface Sci 2012, 365:143-149.
57. Alexiou C., Arnold W., Klein R.J., Parak F.G., Hulin P., Bergemann C., et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000, 60:6641-6648.
58. Frimpong R.A., Hilt J.Z. Magnetic nanoparticles in biomedicine: synthesis, functionalization and applications. Nanomedicine (Lond) 2010, 5:1401-1414.
59. Hofmann-Amtenbrink M., Hofmann H., Montet X. Superparamagnetic nanoparticles - a tool for early diagnostics. Swiss Med Wkly 2010, 140:w13081-13.
60. Chan D.C.F., Kirpotin D.B., Paul A. Bunn. Synthesis and evaluation of colloidal magnetic iron-oxides for the site-specific radiofrequency-induced hyperthermia of cancer. J Magn Magn Mater 1993, 122:374-378.
61. Patra H.K., Banerjee S., Chaudhuri U., Lahiri P., Dasgupta A.K. Cell selective response to gold nanoparticles. Nanomedicine 2007, 3:111-119.
62. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325-327.
63. Han G., Ghosh P., De M., Rotello V.M. Drug and gene delivery using gold nanoparticles. Nanobiotechnology 2007, 3:40-45.
64. Sondi I., Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 2004, 275:177-182.
65. Silver S., Phung L.T., Silver G. Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds. J Ind Microbiol Biotechnol 2006, 33:627-634.
66. Aziz Z., Abu S.F., Chong N.J. A systematic review of silver-containing dressings and topical silver agents (used with dressings) for burn wounds. Burns 2012, 38:307-318.
67. Storm-Versloot M.N., Vos C.G., Ubbink D.T., Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010, 17:CD006478.
68. Beattie M., Taylor J. Silver alloy vs. uncoated urinary catheters: a systematic review of the literature. J Clin Nurs 2011, 20:2098-2108.
69. Nagpal K., Singh S.K., Mishra D.N. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull 2010, 58:1423-1430.
70. De Campos A.M., Sánchez A., Alonso M.J. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001, 224:159-168.
71. Han H.D., Mora E.M., Roh J.W., Nishimura M., Lee S.J., Stone R.L., et al. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 2011, 11:839-845.
72. Makhlof A., Tozuka Y., Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci 2011, 42:445-451.
73. Sanoj Rejinold N., Sreerekha P.R., Chennazhi K.P., Nair S.V., Jayakumar R. Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. Int J Biol Macromol 2011, 49:161-172.
74. Simi C.K., Emilia Abraham T. Hydrophobic grafted and cross-linked starch nanoparticles for drug delivery. Bioprocess Biosyst Eng 2007, 30:173-180.
75. Xiao S., Tong C., Liu X., Yu D., Liu Q., Xue C., et al. Preparation of folate-conjugated starch nanoparticles and its application to tumor-targeted drug delivery vector. Chin. Sci Bull 2006, 51:1693-1697.
76. Ekimov A. Quantum size effect in three-dimensional microscopic semiconductor crystals. ZhETF Pis ma Redaktsiiu 1981, 34:363.
77. Medintz I.L., Mattoussi H., Clapp A.R. Potential clinical applications of quantum dots. Int J Nanomedicine 2008, 3:151-167.
78. Reiss P., Protière M., Li L. Core/Shell semiconductor nanocrystals. Small 2009, 5:154-168.
79. Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008, 5:763-775.
80. Derfus A.M., Chen A.A., Min D.-H., Ruoslahti E., Bhatia S.N. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 2007, 18:1391-1396.
81. Zintchenko A., Susha A.S., Concia M., Feldmann J., Wagner E., Rogach A.L., et al. Drug nanocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals. Mol Ther 2009, 17:1849-1856.
82. Juzenas P., Chen W., Sun Y.-P., Neto Coelho M.A., Generalov R., Generalova N., et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev 2008, 60:1600-1614.
83. Luo G., Long J., Zhang B., Liu C., Ji S., Xu J., et al. Quantum dots in cancer therapy. Expert Opin Drug Deliv 2012, 9:47-58.
84. Hu R., Yong K.-T., Roy I., Ding H., Law W.-C., Cai H., et al. Functionalized near-infrared quantum dots for in vivo tumor vasculature imaging. Nanotechnology 2010, 21:145105.
85. Zhang Q., Zha L., Ma J., Liang B. A novel route to prepare pH- and temperature-sensitive nanogels via a semibatch process. J Colloid Interface Sci 2009, 330:330-336.
86. Mimi H., Ho K.M., Siu Y.S., Wu A., Li P. Polyethyleneimine-Based Core-Shell Nanogels. A promising siRNA carrier for argininosuccinate synthetase mRNA knockdown in HeLa cells. J Control Release 2012, 28:158123-158130.
87. Wu W., Shen J., Gai Z., Hong K., Banerjee P., Zhou S. Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery. Biomaterials 2011, 32:9876-9887.
88. Dumville J.C., O'Meara S., Deshpande S., Speak K. Hydrogel dressings for healing diabetic foot ulcers. Cochrane Database Syst Rev 2011, 9:CD009101.
89. Skulason S., Holbrook W.P., Thormar H., Gunnarsson G.B., Kristmundsdottir T. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. J Oral Pathol Med 2012, 41:61-67.
90. Han S., Cao S., Wang Y., Wang J., Xia D., Xu H., et al. Self-assembly of short peptide amphiphiles: the cooperative effect of hydrophobic interaction and hydrogen bonding. Chemistry 2011, 17:13095-13102.
91. Meng Q., Kou Y., Ma X., Liang Y., Guo L., Ni C., et al. Tunable self-assembled peptide amphiphile nanostructures. Langmuir 2012, 28:5017-5022.
92. Fraysse-Ailhas C., Graff-Meyer A., Rigler P., Mittelhozer C., Raman S., Aebi U., et al. Peptide nanoparticles for drug delivery applications. Eur Cell Mater 2007, 14:115.
93. Raman S., Machaidze G., Lustig A., Aebi U., Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2006, 2:95-102.
94. Bawa R., Fung S.-Y., Shiozaki A., Yang H., Zheng G., Keshavjee S., Liu M. Self-assembling peptide-based nanoparticles enhance cellular delivery of the hydrophobic anticancer drug ellipticine through caveolae-dependent endocytosis. Nanomedicine 2012, 8:647-654.
95. Naskar J., Roy S., Joardar A., Das S., Banerjee A. Self-assembling dipeptide-based nontoxic vesicles as carriers for drugs and other biologically important molecules. Org Biomol Chem 2011, 9:6610-6615.
96. Tagami T., Ernsting M.J., Li S.-D. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release 2011, 152:303-309.
97. Lutz R.J., Whiteman K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009, 1:548-551.
98. Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2010, 103:317-324.
99. Keam S.J., Scott L.J., Curran M.P. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 2002, 63:2521-2554.
100. Coco Lo F., Ammatuna E., Noguera N.L. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2005, 4:57-67.
101. Le U.M., Shaker D.S., Sloat B.R., Cui Z. A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Dev Ind Pharm 2008, 34:413-418.
102. Pouponneau P., Leroux J.-C., Soulez G., Gaboury L., Martel S. Co-encapsulation of magnetic nanoparticles and doxorubicin into biodegradable microcarriers for deep tissue targeting by vascular MRI navigation. Biomaterials 2011, 32:3481-3486.
103. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res 1986, 46:6387-6392.
104. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
105. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007, 15:457-464.
106. Liberti P.A., Rao C.G., Terstappen L.W.M.M. Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood. J Magn Magn Mater 2001, 225:301-307.
107. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
108. Bae Y.H. Drug targeting and tumor heterogeneity. J Control Release 2009, 133:2-3.
109. Paul F., Roath S., Melville D., Warhurst D.C., Osisanya J.O. Separation of malaria-infected erythrocytes from whole blood: use of a selective high-gradient magnetic separation technique. Lancet 1981, 2:70-71.
110. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
111. Torchilin V. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
112. Richmond A., Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 2008, 1:78-82.
113. Elsherbini A.A.M., Saber M., Aggag M., El-Shahawy A., Shokier H.A.A. Magnetic nanoparticle-induced hyperthermia treatment under magnetic resonance imaging. Magn Reson Imaging 2011, 29:272-280.
114. Strebhardt K.K., Ullrich A.A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8:473-480.
115. Kumar C.S.S.R., Mohammad F. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev 2011, 63:789-808.
116. Shan Z., Li C., Zhang X., Oakes K.D., Servos M.R., Wu Q., et al. Temperature-dependent selective purification of plasmid DNA using magnetic nanoparticles in an RNase-free process. Anal Biochem 2011, 412:117-119.
117. Broz P., Benito S.M., Saw C., Burger P., Heider H., Pfisterer M., et al. Cell targeting by a generic receptor-targeted polymer nanocontainer platform. J Control Release 2005, 102:475-488.
118. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009, 13:256-262.
119. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 1991, 88:5572-5576.
120. Al-Deen F.N., Ho J., Selomulya C., Ma C., Coppel R. Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine. Langmuir 2011, 27:3703-3712.
121. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146.
122. Ghaghada K., Saul J., Natarajan J., Bellamkonda R., Annapragada A. Folate targeting of drug carriers: a mathematical model. J Control Release 2005, 104:113-128.
123. Liang G., Cai S., Zhang P., Peng Y., Chen H., Zhang S., et al. Magnetic relaxation switch and colorimetric detection of thrombin using aptamer-functionalized gold-coated iron oxide nanoparticles. Anal Chim Acta 2011, 689:243-249.
124. Hillaireau H., Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
125. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18:410-414.
126. Doherty G.J., McMahon H.T. Mechanisms of endocytosis. Annu Rev Biochem 2009, 78:857-902.
127. Weissleder R., Moore A., Mahmood U., Bhorade R., Benveniste H., Chiocca E.A., et al. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000, 6:351-355.
128. Ziello J., Huang Y. Cellular endocytosis and gene delivery. Mol Med 2010, 16:1.
129. Perez J.M., Josephson L., Weissleder R. Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. Chembiochem 2004, 5:261-264.
130. Khalil I., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006, 58:32-45.
131. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195-206.
132. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
133. Joliot A., Pernelle C., Deagostini-Bazin H., Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 1991, 88:1864-1868.
134. Bitler B.G., Schroeder J.A. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov 2010, 5:99-108.
135. Dietz G.P.H., Bδhr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 2004, 27:85-131.
136. Snyder E.L., Dowdy S.F. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2005, 2:43-51.
137. Chen H.-C.G., Chiou S.-T., Zheng J.-Y., Yang S.-H., Lai S.-S., Kuo T.-Y. The nuclear localization signal sequence of porcine circovirus type 2 ORF2 enhances intracellular delivery of plasmid DNA. Arch Virol 2011, 156:803-815.
138. Alves I.D., Bechara C., Walrant A., Zaltsman Y., Jiao C.-Y., Sagan S. Relationships between membrane binding. Affinity and cell internalization efficacy of a cell-penetrating peptide: penetratin as a case study. Plos One 2011, 6:e24096.
139. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008, 36:4158-4171.
140. Morris M.C., Depollier J., Mery J., Heitz F., Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001, 19:1173-1176.
141. Deshayes S., Morris M., Heitz F., Divita G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 2008, 60:537-547.
142. Majoros I.J., Williams C.R., Becker A., Baker J.R.J. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. WIREs Nanomed Nanobiotechnol 2009, 1:502-510.
143. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009, 34:1629-1636.
144. Yang D., Yu L., Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers 2011, 3:17-42.
145. Ehrlich A., Booher S., Becerra Y., Borris D.L., Figg W.D., Turner M.L., et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004, 50:533-540.
146. Peng G., Tisch U., Adams O., Hakim M., Shehada N., Broza Y.Y., et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 2009, 4:669-673.
147. Liu Z., Chen K., Davis C., Sherlock S., Cao Q., Chen X., et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008, 68:6652-6660.
148. Sohn J.H., Choi H.J., Lee J.T., Lee J.D., Kim J.H., Moon Y.M., et al. Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma. Oncology 2009, 76:1-9.
149. Savla R., Taratula O., Garbuzenko O., Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release 2011, 153:16-22.
150. Gao X., Cui Y., Levenson R., Chung L., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969-976.
151. Mehta R.R., Yamada T., Taylor B.N., Christov K., King M.L., Majumdar D., et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011, 14:355-369.
152. Shaughnessy L.M., Hoppe A.D., Christensen K.A., Swanson J.A. Membrane perforations inhibit lysosome fusion by altering pH and calcium in Listeria monocytogenes vacuoles. Cell Microbiol 2006, 8:781-792.
153. Salt C., Lennox A., Takagaki M., Maguire J., Hosmane N. Boron and gadolinium neutron capture therapy. Russ Chem Bull 2004, 53:1871-1888.
154. Günther M., Lipka J., Malek A., Gutsch D., Kreyling W., Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011, 77:438-449.
155. Walker S.J. Boron neutron capture therapy: principles and prospects. Radiography 1998, 4:211-219.
156. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Kawakami T., et al. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 2004, 43:5618-5628.
157. Barth R.F., Coderre J.A., Vicente M.G.H., Blue T.E. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005, 11:3987-4002.
158. Berg K., Selbo P., Prasmickaite L., Tjelle T., Sandvig K., Moan D., et al. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res 1999, 59:1180-1183.
159. Hwang K.C., Lai P.D., Chiang C.-S., Wang P.-J., Yuan C.-J. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells. Biomaterials 2010, 31:8419-8425.
160. Strømhaug P.E., Berg T.O., Berg K., Seglen P.O. A novel method for the study of autophagy: destruction of hepatocytic lysosomes, but not autophagosomes, by the photosensitizing porphyrin tetra(4-sulphonatophenyl)porphine. Biochem J 1997, 321:217-225.
161. Prasmickaite L., Hogset A., Berg K. Evaluation of different photosensitizers for use in photochemical gene transfection. Photochem Photobiol 2001, 73:388-395.
162. Hawthorne M.F. New horizons for therapy based on the boron neutron capture reaction. Mol Med Today 1998, 4:174-181.
163. Johnson P.C., Wheat L.J., Cloud G.A., Goldman M., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002, 137:105-109.
164. Martino R.R. Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature. Curr Med Res Opin 2004, 20:485-504.
165. Szebeni J., Baranyi L., Savay S., Lutz H.U., Jelezarova E., Bünger R., et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J Liposome Res 1999, 10:467-481.
166. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
167. Szebeni J., Muggia F., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention. Adv Drug Deliv Rev 2011, 63:1020-1030.
168. Cagnoni P.J. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2001, 49:81-86.
169. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.
170. Moen M.D., Lyseng-Williamson K.A., Scott L.J. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009, 69:361-392.
171. Bowden R., Chandrasekar P., White M., Li X., Pietrelli L., Gurwith M., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002, 35:359-366.
172. Working P.K. Amphotericin B, colloidal dispersion. Pre-clinical review. Chemotherapy 1999, 45:15-26.
173. Petre C.E., Dittmer D.P. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine 2007, 2:277-288.
174. Chang H.-I., Yeh M.-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2011, 7:49-60.
175. Sadava D.D., Coleman A.A., Kane S.E.S. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res 2002, 12:301-309.
176. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
177. Batist G., Ramakrishnan G., Lee L.W. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
178. O'Brien M., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX (TM)/Doxil (R)) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
179. Yuan Y., Orlow S., Curtin J., Downey A., Muggia F. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience 2008, 2:111.
180. Boman N.L.N., Masin D.D., Bally M.B.M. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994, 54:2830-2833.
181. Mayer L.D.L., Masin D.D., Bally M.B.M. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 1995, 71:482-488.
182. Garcia-Marco J.A.J., Panizo C.C., Vela J.A.J.G. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009, 115:1892-1898.
183. Gambling D., Hughes T., Martin G., Horton W., Manvelian G. A comparison of Depodur (TM), a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg 2005, 100:1065-1074.
184. Zeidan A., Wang E.S., Wetzler M. Pegasparaginase: where do we stand?. Expert Opin Biol Ther 2009, 9:111-119.
185. Pradhananga S.S., Wilkinson I.I., Ross R.J.M.R. Pegvisomant: structure and function. J Mol Endocrinol 2002, 29:11-14.
186. Garay R, Labaune J. Immunogenicity of Polyethylene Glycol (PEG) 2011:1-4.
187. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, neulasta®). Curr Pharm Des 2004, 10:1235-1244.
188. Sanchez-Fructuoso A., Guirado L., Ruiz J.C., Torregrosa V., Gonzalez E., Suarez M.L., et al. Anemia control in kidney transplant patients treated with methoxy polyethylene glycol-epoetin beta (Mircera): The Anemiatrans Group. Transpl P 2010, 42:2931-2934.
189. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur J Nanomedicine 2012, 4:33-53.
190. Hamad I., Hunter A.C., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008, 46:225-232.
191. Foster G.R. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010, 70:147-165.
192. Zampros I., Praidou A., Brazitikos P., Ekonomidis P., Androudi S. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012.
193. Garratty G. Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 2007, 87-95.
194. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
195. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
196. Veronese F.M., Mero A., Pasut G. Protein PEGylation, basic science and biological applications 2009, 1-21. Birkhäuser Verlag, Switzerland.
197. Spaia S. Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure. Hippokratia 2010, 15:22-26.
198. Simberg D., Park J.-H., Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
199. Moore A., Weissleder R., Bogdanov A. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997, 7:1140-1145.
200. Gradishar W.J.W., Tjulandin S.S., Davidson N.N., Shaw H.H., Desai N.N., Bhar P.P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
201. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
202. Junghanns J.-U.A.H., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008, 3:295-309.
203. Webster R., Elliott V., Park B.K., Walker D., Hankin M., Taupin P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated. Biologicals 2009, 127-146. Birkhäuser Verlag, Switzerland.
204. Szebeni J., Bedocs P., Rozsnyay Z., Weiszhár Z., Urbanics R., Rosivall L., et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome. Nanomedicine 2012, 8:176-184.
205. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003, 14:1430-1437.
206. Richter A.W., Akerblom E. Polyethylene-glycol reactive antibodies in man - titer distribution in allergic patients treated with monomethoxy polyethylene-glycol modified allergens or placebo, and in healthy blood-donors. Int Arch Allergy Appl Immunol 1984, 74:36-39.
207. Tziomalos K., Athyros V.G. Fenofibrate: a novel formulation (Triglide (TM)) in the treatment of lipid disorders: a review. Int J Nanomedicine 2006, 1:129-147.
208. Hunziker P. "Knowledge-based (personalized) medicine" instead of 'evidence-based (cohort) medicine' - applying nanoscience and computational science to create an effective, safe, curative and affordable medicine of the future. Eur J Nanomed 2012, 1-2.